Cipla’s arm receives USFDA approval to market generic Bupropion Hydrochloride tablets

30 Aug 2016 Evaluate

Cipla’s US subsidiary, InvaGen Pharmaceuticals has received final approval from the United States Food and Drug Administration (USFDA) to market a generic Bupropion Hydrochloride extended release tablets (XL), 150 mg and 300 mg, used for treatment of major depressive disorder. The company's tablets are generic versions of Valeant's Wellbutrin XL tablets in the same strengths. Wellbutrin XL tablets and generic equivalents had US sales of approximately $792 million for the 12 month period ending June 2016, according to IMS Health.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.


Cipla Share Price

1434.60 0.00 (0.00%)
14-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1700.55
Dr. Reddys Lab 1186.45
Cipla 1434.60
Zydus Lifesciences 884.00
Lupin 2195.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×